Subgroup analyses in randomized clinical trials: Statistical and regulatory issues

Journal of Biopharmaceutical Statistics

Volumn 15, Issue 5, 2005, Pages 869-882

  Grouin, Jean Marie ^a   Coste, Maylis ^b   Lewis, John ^c  

^a UNIVERSITÉ DE ROUEN   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c Silverton Lodge   (United Kingdom)

Author keywords

Randomized clinical trials; Regulatory claims; Statistical issues; Subgroup analyses

Indexed keywords

CORTICOSTEROID; NATURAL PRODUCT;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; REVIEW; STATISTICAL ANALYSIS; STEROID THERAPY; VALIDATION PROCESS;

DATA INTERPRETATION, STATISTICAL; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS; SAMPLE SIZE;

EID: 22544469981     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1081/BIP-200067988     Document Type: Review

References (22)

1. Biesheuvel, E. H., Hothorn, L. A. (2003). Protocol designed subgroup analyses in multiarmed clinical trials: Multiplicity aspects. J. Biopharm. Stat. 13(4):663-673.
2. Bristol, D. R. (1993). Protocol strategies for addressing subgroup analyses and p-value adjustments. Drug Info. J. 27:611-614.
3. Bristol, D. R. (1997). P-value adjustments for subgroup analyses. J. Biopharm. Stat. 7:313-321.
4. Cox, D. R., McCullough, P. (1982). Some aspects of covariance. Biometrics 38:541-561.
5. CPMP. (2004). Points to consider on adjustment for baseline covariates. Stat. Med. 23:701-709.
6. CPMP/EWP/908/99. (2002). Points to consider on multiplicity issues in clinical trials. London: EMEA.
7. CPMP/EWP/1080/00. (1997). Note for guidance on medicinal products in the treatment of Alzheimer's disease. London: EMEA.
8. Donner, A. (1993). Issues of interpretation arising from analyses of multiple subgroups in clinical trials. Drug Info. J. 27:587-595.
9. Fleming, T. R. (1995). Interpretation of subgroup analyses in clinical trials. Drug Info. J. 29:16818-16878.
10. Ford, I., Norrie, J., Ahmadi, S. (1995). Model inconsistency, illustrated by the Cox proportional hazards model. Stat. Med. 14:735-746.
11. Gail, M. H., Wieland, S., Piantadosi, S. (1984). Biased estimates of treatment effect in randomised experiments with non-linear regressions and omitted covariates. Biometrika 71:431-444.
12. Grouin, J.-M., Day, S., Lewis, J. (2004). Adjustment for baseline covariates: An introductory note. Stat. Med. 23:697-699.
13. Koch, G. G. (1997). Discussion of "P-value adjustments for sub-group analyses". J. Biopharm. Stat. 7:323-331.
14. Koch, G. G., Stuart, A. G. (1996). Statistical considerations for multiplicity in confirmatory protocols. Drug Info. J. 30:523-533.
15. Pocock, S. J., Assmann, S. E., Enos, L. E., Kasten, L. E. (2002). Subgroup analysis, covariate adjustment and baseline comparison in clinical trial reporting: Current practice and problems. Stat. Med. 21:2917-2930.
16. Senn, S. J. (1989). Covariate imbalance and random allocation in clinical trials. Stat. Med. 8:467-475.
17. Senn, S. J. (1994). Testing for baseline imbalance in clinical trials. Stat. Med. 13:1715-1726.
18. Senn, S. J. (1995). Base logic: Tests of baseline balance in randomised clinical trials. Clin. Research & Reg. Affairs 12(3):171-182.
19. Senn, S. J. (1997). Statistical Issues in Drug Development. New York: Wiley.
20. Simon, R. (1988). Statistical tools for subset analysis in clinical trials. Recent Results in Cancer Research 111:55-66.
21. Simon, R. (2002). Bayesian subset analysis: Application to studying treatment-by-gender interactions. Stat. Med. 21:2909-2916.
22. Struthers, C. A., Kalbfleisch, J. D. (1986). Misspecified proportional hazard models. Biometrika 73(2):363-369.